Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Arcturus Therapeutics Holdings Inc
ARCTCurrent price
17.42 USD
+0.87 USD (+5.26%)
Last closed
16.74 USD
Company
arcturusrx.com
ISIN
US03969T1097
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
439 899 360 USD
Yield for 12 month
-45.90 %
1Y
3Y
5Y
10Y
15Y
ARCT
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Address: 10628 Science Center Drive, San Diego, CA, United States, 92121
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
79.47 USDP/E ratio
–Dividend Yield
–Current Year
+157 748 000 USD
Last Year
+205 755 000 USD
Current Quarter
+38 815 000 USD
Last Quarter
+45 976 000 USD
Current Year
+154 791 000 USD
Last Year
+62 704 000 USD
Current Quarter
+41 673 000 USD
Last Quarter
+45 076 000 USD
Key Figures ARCT
1 year
3 years
5 years
10 years
EBITDA
-77 007 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-12.15 %
PEG Ratio
–
Return On Equity TTM
-23.12 %
Wall Street Target Price
79.47 USD
Revenue TTM
160 399 008 USD
Book Value
9.67 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-7.70 %
Dividend Yield
–
Gross Profit TTM
62 948 000 USD
Earnings per share
-2.33 USD
Diluted Eps TTM
-2.33 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-39.05 %
Dividend Analytics ARCT
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History ARCT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:7
Payout Ratio
–
Last Split Date
16.11.2017
Dividend Date
16.11.2017
Stock Valuation ARCT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
2.48
Enterprise Value Revenue
1.81
Price Sales TTM
2.74
Enterprise Value EBITDA
-25.67
Price Book MRQ
1.78
Financials ARCT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ARCT
For 52 weeks
14.93 USD
45.00 USD
50 Day MA
19.03 USD
Shares Short Prior Month
4 484 383
200 Day MA
25.11 USD
Short Ratio
9.41
Shares Short
4 368 940
Short Percent
25.29 %
BeatStart